After learning you have prediabetes, you may work with your healthcare team to make changes to your eating style, weight ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 ...

A recent study by Kaiser Permanente highlights how a short-term strategy called a brief intervention (BI) can help adults ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

“Results from STEP UP further strengthen the clinical profile of semaglutide for the treatment of obesity, in addition to the health benefits already established with Wegovy ®, including ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy ... The company’s second trial, STEP UP T2D, which targets obese patients with type 2 diabetes as part of its global STEP ...

The company is also testing semaglutide 7.2 mg in a separate phase 3 study, STEP UP T2D, which is looking at the higher dose in adults with Type 2 diabetes and obesity. That trial is expected to ...

“Results from STEP UP further strengthen the clinical profile of semaglutide for the treatment of obesity, in addition to the health benefits already established with Wegovy ®, including ...

The results from the second semaglutide 7.2 mg phase 3 trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next few months. Detailed results from the STEP UP ...